209 related articles for article (PubMed ID: 36814229)
1. Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country.
Joudeh N; Sawafta E; Abu Taha A; Hamed Allah M; Amer R; Odeh RY; Salameh H; Sabateen A; Aiesh BM; Zyoud SH
BMC Infect Dis; 2023 Feb; 23(1):106. PubMed ID: 36814229
[TBL] [Abstract][Full Text] [Related]
2. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Open-Labeled, Prospective Controlled Study to Assess the Efficacy of Frontline Empirical Intravenous Piperacillin/Tazobactam Monotherapy in Comparison with Ceftazidime Plus Amikacin for Febrile Neutropenia in Pediatric Oncology Patients.
Kamonrattana R; Sathitsamitphong L; Choeyprasert W; Charoenkwan P; Natesirinilkul R; Fanhchaksai K
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2733-2737. PubMed ID: 31554370
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia.
Marini BL; Hough SM; Gregg KS; Abu-Seir H; Nagel JL
Support Care Cancer; 2015 Aug; 23(8):2287-95. PubMed ID: 25576429
[TBL] [Abstract][Full Text] [Related]
5. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
Hess U; Böhme C; Rey K; Senn HJ
Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
[TBL] [Abstract][Full Text] [Related]
6. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic susceptibility of Gram-negatives isolated from bacteremia in children with cancer. Implications for empirical therapy of febrile neutropenia.
Castagnola E; Caviglia I; Pescetto L; Bagnasco F; Haupt R; Bandettini R
Future Microbiol; 2015; 10(3):357-64. PubMed ID: 25812459
[TBL] [Abstract][Full Text] [Related]
8. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
[TBL] [Abstract][Full Text] [Related]
9. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
Marie JP; Vekhoff A; Pico JL; Guy H; Andremont A; Richet H
J Antimicrob Chemother; 1998 Jun; 41 Suppl D():57-64. PubMed ID: 9688452
[TBL] [Abstract][Full Text] [Related]
10. A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
Metan G; Kaynar L; Yozgat N; Elmali F; Kürkçüoglu CA; Alp E; Çetin M
Infez Med; 2017 Mar; 25(1):33-37. PubMed ID: 28353453
[TBL] [Abstract][Full Text] [Related]
11. Bacterial Isolates and Characteristics of Children With Febrile Neutropenia on Treatment for Cancer at a Tertiary Hospital in Western Kenya.
Kipchumba SK; Njuguna FM; Nyandiko WM
JCO Glob Oncol; 2024 Feb; 10():e2300313. PubMed ID: 38301180
[TBL] [Abstract][Full Text] [Related]
12. Dissecting bloodstream infections in febrile neutropenic patients with hematological malignancies, a decade-long single center retrospective observational study (2009-2019).
El Omri H; Padmanabhan R; Taha RY; Kassem N; Elsabah H; Ellahie AY; Santimano AJJ; Al-Maslamani MA; Omrani AS; Elomri A; El Omri A
J Infect Public Health; 2024 Jan; 17(1):152-162. PubMed ID: 38029491
[TBL] [Abstract][Full Text] [Related]
13. The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
Clerici D; Oltolini C; Greco R; Ripa M; Giglio F; Mastaglio S; Lorentino F; Pavesi F; Farina F; Liberatore C; Castiglion B; Tassan Din C; Bernardi M; Corti C; Peccatori J; Scarpellini P; Ciceri F; Castagna A
Int J Antimicrob Agents; 2021 Jun; 57(6):106335. PubMed ID: 33838223
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
Cometta A; Zinner S; de Bock R; Calandra T; Gaya H; Klastersky J; Langenaeken J; Paesmans M; Viscoli C; Glauser MP
Antimicrob Agents Chemother; 1995 Feb; 39(2):445-52. PubMed ID: 7726513
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
Serefhanoglu K; Ersoy Y; Serefhanoglu S; Aydogdu I; Kuku I; Kaya E
Ann Acad Med Singap; 2006 Jan; 35(1):11-6. PubMed ID: 16470268
[TBL] [Abstract][Full Text] [Related]
16. Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy.
Chen CY; Tang JL; Hsueh PR; Yao M; Huang SY; Chen YC; Chen YC; Shen MC; Wang CH; Tsai W; Chang SC; Tien HF; Luh KT
J Formos Med Assoc; 2004 Jul; 103(7):526-32. PubMed ID: 15318274
[TBL] [Abstract][Full Text] [Related]
17. [Piperacillin/tazobactam plus amikacin vs. piperacilin/tazobactam: treatment for children with febrile neutropenia].
Pacheco-Rosas DO; Peregrino-Bejarano L; López-Aguilar JE; Juan-Shum L; Miranda-Novales MG
Rev Med Inst Mex Seguro Soc; 2019 Jul; 57(2):65-73. PubMed ID: 31617992
[TBL] [Abstract][Full Text] [Related]
18. Emerging bacterial resistance patterns in febrile neutropenic patients: experience at a tertiary care hospital in Pakistan.
Khan MA; Siddiqui BK; Shamim A; Yosuf MA; Ahmed U; Zakiullah N; Burney IA
J Pak Med Assoc; 2004 Jul; 54(7):357-60. PubMed ID: 15449917
[TBL] [Abstract][Full Text] [Related]
19. Application of the Weighted-Incidence Syndromic Combination Antibiogram (WISCA) to guide the empiric antibiotic treatment of febrile neutropenia in oncological paediatric patients: experience from two paediatric hospitals in Northern Italy.
Liberati C; Donà D; Maestri L; Petris MG; Barbieri E; Gallo E; Gallocchio J; Pierobon M; Calore E; Zin A; Brigadoi G; Mariani M; Mesini A; Saffioti C; Ugolotti E; Gregori D; Giaquinto C; Castagnola E; Biffi A
Ann Clin Microbiol Antimicrob; 2024 Feb; 23(1):16. PubMed ID: 38360651
[TBL] [Abstract][Full Text] [Related]
20. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
Sanz MA; López J; Lahuerta JJ; Rovira M; Batlle M; Pérez C; Vázquez L; Julià A; Palau J; Gutiérrez M; Capote FJ; Ramos F; Benlloch L; Larrea L; Jarque I;
J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
